An interventional study of Digital Discharge Planning Application and Standard Discharge Planning in Diabetes (DM), sponsored by Universitas Muhammadiyah Surakarta. Not yet recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Universitas Muhammadiyah Surakarta · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Diabetes Mellitus with a site in Indonesia — 7 open to participants now, 9 under way, 1 of them phase 3. Diabetes Mellitus · Indonesia.
Among the 46 studies in Diabetes Mellitus with a site in Indonesia, this one is the 17th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 with no phase, and was the 45th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →7 of the 46 studies in Diabetes Mellitus with a site in Indonesia are open now. Recruiting first, the newest first:
Indonesia University · Sites in Indonesia
Ages 8–40 · Healthy volunteers
Tarumanagara University · Sites in Indonesia
Ages 30+ · Healthy volunteers
Andalas University · Sites in Indonesia
Ages 18+ · Healthy volunteers
Tarumanagara University · Sites in Indonesia
Ages 18+ · Healthy volunteers
Universitas Sebelas Maret · Sites in Indonesia
Ages 40–60
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 3 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is close to the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 84 across the 29 interventional studies, 1,584 across the 17 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 46 have an industry lead sponsor. The 10 most frequent:
Universitas Muhammadiyah Surakarta is the lead sponsor of 11 studies on the registry; 4 are open to participants now.
Universitas Muhammadiyah Surakarta has 1 study filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus with a site in Indonesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229794St Elisabeth School Health ScienceEffect of Foot-ankle Exercise Using Elastic Band | 2026-11-30 |
| NCT07126041Oxford University Clinical Research Unit IndonesiaScalable Public Health Empowerment, Research, and Education Sites (SPHERES) | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Diabetes Mellitus with a site in Indonesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Diabetes mellitus is a chronic disease that requires continuous self-management to prevent complications and hospital readmissions. However, discharge planning in many hospitals is often delivered verbally and lacks structured follow-up after patients return home, which may lead to poor self-management behaviors.
This study aims to evaluate the effectiveness of a digital discharge planning intervention delivered through a mobile application to improve self-management among patients with diabetes mellitus after hospital discharge. The intervention is based on the Chronic Care Model and includes educational materials, reminders, and monitoring tools related to seven dimensions of diabetes self-management.
A randomized controlled trial with a parallel-group design will be conducted among patients with diabetes mellitus. Participants in the intervention group will receive digital discharge planning through a mobile application for 90 days after discharge, while the control group will receive standard discharge planning provided by the hospital. Primary outcomes include patient self-management behavior, while secondary outcomes include glycemic control and hospital readmission within 90 days.
Diabetes mellitus is one of the most prevalent chronic diseases worldwide and requires long-term self-management to maintain glycemic control and prevent complications. Effective discharge planning plays an important role in preparing patients to manage their condition independently after leaving the hospital. However, in many clinical settings, discharge planning is often delivered verbally and without structured follow-up, which may limit patients' ability to maintain appropriate self-management behaviors.
This study develops and evaluates a digital discharge planning model delivered through a mobile application to support patients with diabetes mellitus after hospital discharge. The intervention is theoretically grounded in the Chronic Care Model and supported by nursing theories including Orem's Self-Care Deficit Theory, Watson's Human Caring Theory, and Pender's Health Promotion Model.
The mobile application includes several features designed to support diabetes self-management based on the Diabetes Canada framework, including healthy eating, physical activity, blood glucose monitoring, medication adherence, problem solving, reducing risks, and healthy coping. The application provides educational materials, reminders, daily activity tracking, and feedback to encourage patient engagement and adherence to self-management practices.
A randomized controlled trial with a parallel-group design will be conducted to evaluate the effectiveness of the intervention. Participants will be randomly assigned to either the intervention group receiving digital discharge planning through the mobile application or the control group receiving standard discharge planning provided by the hospital. The intervention period will last for 90 days following hospital discharge. The study will assess the impact of the digital discharge planning model on self-management behaviors, glycemic control, and hospital readmission among patients with diabetes mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive digital discharge planning through a mobile application for 90 days after hospital discharge.
Behavioral: Digital Discharge Planning Application
Participants receive standard discharge planning routinely provided by the hospital.
Behavioral: Standard Discharge Planning
A mobile health application designed to support diabetes self-management after hospital discharge, including education, reminders, and monitoring tools for 90 days.
Participants receive standard discharge planning routinely provided by the hospital according to usual care procedures.
Change in diabetes self-management score
Diabetes self-management will be assessed using an adapted Indonesian version of the Summary of Diabetes Self-Care Activities (SDSCA) questionnaire consisting of 21 items across seven domains (healthy eating, physical activity, blood glucose monitoring, medication adherence, problem solving, risk reduction, and healthy coping). Each item is scored on a 5-point Likert scale (1-5) reflecting frequency of behavior during the past 7 days. Total scores range from 21 to 105, with higher scores indicating better diabetes self-management behavior.
Time frame: Baseline to 90 days after hospital discharge
Change in HbA1c level
Glycemic control will be assessed by measuring glycated hemoglobin (HbA1c) levels before the intervention and at the end of the 90-day follow-up period.
Time frame: Baseline to 90 days
Hospital readmission within 90 days
Hospital readmission due to diabetes-related complications within 90 days after discharge will be recorded from hospital records.
Time frame: Within 90 days after hospital discharge
Plan to share: No — Individual participant data will not be publicly shared due to privacy and confidentiality considerations. Data may be available from the principal investigator upon reasonable request.
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 6 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitas Muhammadiyah Surakarta